Social networks
711Activities
Technologies
Entity types
Location
Scheelevägen 1, 223 63 Lund, Sweden
Lund
Sweden
Employees
Scale: 2-10
Estimated: 10
Engaged corporates
0Added in Motherbase
3 months, 2 weeks agoInnovation in pain relief
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
PN6047 is Phase II ready!
CNS, Neurology, Chronic Pain Treatment, BioPharma, Bioscience, Chemistry, Biotechnology, Pharmacology, Proteins, DOR agonists, and Delta opioid receptor
Latest News from PharmNovo. Learn more about pain, neuropathic pain, chronic pain. Treatment with our lead candidate PN6047. Therapy market, our networks. There is a huge unmet medical need for people suffering from chronic pain.